-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, AstraZeneca announced the withdrawal of its Imfinzi product for use in previously treated adults with locally advanced or metastatic bladder cancer indications.
It is reported that because Imfinzi did not meet the U.
"Imfinzi" is AstraZeneca's first immunotherapy drug.
Urothelial carcinoma is the most common type of bladder cancer, and its morbidity and mortality account for the first place among male genitourinary system tumors.
In May 2017, based on the safety and efficacy data of Phase I/II clinical trials, the FDA approved Imfinzi for the treatment of patients with locally advanced or metastatic urothelial cancer.
On March 30, 2020, based on the positive results of the Phase III clinical trial CASPIAN, Imfinzi was approved in the United States as a first-line treatment for adult patients with extensive-stage small cell lung cancer (ES-SCLC).
Unfortunately, in the Phase III clinical trials for patients with bladder cancer, Imfinzi, Imfinzi + tremelimumab, the first-line treatment of unresectable, stage IV (metastatic) bladder cancer patients, failed to bring significant results compared with standard treatments.
Dave Fredrickson, Executive Vice President of AstraZeneca’s Oncology Business Unit, said: “Immunotherapy has developed rapidly in the past few years, bringing unprecedented new options to patients.
Leave a message here
